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Response to: ‘Will SPAR be useful in the usual 
patients with scleroderma?’ by Chattopadhyay 
et al
Thank you very much for your interest in our article ‘Predic-
tion of progression of interstitial lung disease in patients with 
systemic sclerosis: the SPAR model’1 and your precious ques-
tions ‘Will SPAR be useful in the usual scleroderma patients?’.2 
We are glad to respond as below.
ExtErnal validity of thE Study cohort
The external validity of the patients recruited is unclear. The 
authors may like to provide their cohort numbers and how many 
of them fulfilled the inclusion criteria.
Regarding the question on the external validity of the study 
cohort, we would like to stress that our study cohort focused on 
patients with mild interstitial lung disease (ILD) on high resolu-
tion computer tompgraph (HRCT), without defining a limit for 
forced vital capacity (FVC). That is the reason why our patients 
had an average normal FVC. We disagree that patients with 
milder ILD and normal FVC are uncommon in clinical prac-
tice—please see our recent study.3 In fact, many patients with 
(milder) ILD might be missed if only lung function testing is used 
for screening.
However, we agree that these patients have not been included 
in recent interventional clinical trials such as scleroderma 
lung study (SLS) 1 and 2 which have concentrated on a more 
severe subpopulation with decreased FVC. Thus, whether the 
progression of patients with mild systemic sclerosis (SSc)-ILD 
can be successfully prevented with specific treatments needs 
to be shown. Notably, the ongoing large randomised placebo 
controlled SENSCIS trial, which is testing nintedanib versus 
placebo in patients with SSc-ILD, recruits patients with HRCT 
involvement >10% and no upper limit of FVC.4 Thus, post-hoc 
analysis of this trial in the group of patient with HRCT involve-
ment of 10%–20% and ‘normal’ FVC might partially address 
this question.
In the derivation cohort (Zurich cohort) to the present study, 
we have included 397 patients with SSc with complete data, 
among which 158 patients had ILD. A total of 98 patients (62%) 
fulfilled the inclusion criteria of mild ILD. Base on this result, we 
assume that the current study cohort represents a large subpop-
ulation of patients with SSc-ILD.
thE StatuS of arthritiS
The authors found ‘arthritis ever’ to be significant after multi-
variate analysis, though a previous study did not show any asso-
ciation of arthritis and ILD progression. Was baseline presence 
of arthritis also significant?
Regarding the question on the status of arthritis, the cited 
study looked at a different study population: this was a mixture 
of patients with mild and advanced SSc-ILD, follow-up time 
was longer and a different definition of SSc-ILD progression 
was used.5 Prediction factors for the disease subgroup of more 
advanced SSc-ILD might be very different from patients with 
mild SSc-ILD.
The type of arthritis was as follows: only 6.1% patients ever 
had erosive arthritis in the derivation cohort, and the pres-
ence of anti-cyclic citrullinated peptide (CCP) was low in our 
cohorts (3.5%~6.5%). Methotrexate was the most frequently 
used immunosuppressant (26.5%) in our study, but we are 
unaware whether this was given for the indication of arthritis 
or for other reasons, for example, skin fibrosis. Current arthritis 
only showed no significant association with ILD progression in 
the multivariate analysis, indicating that previous inflammatory 
disease including arthritis is an important parameter for disease 
characterisation.
PrEdictivE PErformancE of thE SPar modEl
The best multivariate predictive model in this study (model 3: 
SpO2 ≤94%+ arthritis ever) has a sensitivity of only 44%- thus 
more than half of the progressors would not be detected.
Regarding the question on the predictive performance of the 
SPAR model, as shown in table 4 of our paper,1 for example, 
in the derivation cohort, 91.7% of patients with SPAR score=2 
actually had ILD progression, 92.6% of patients with SPAR 
score=0 actually did not have ILD progression. Moreover, 
84.0% of ILD progressors had a SPAR score of 1 or 2, 98.6% 
of non-progressors had a SPAR score of 0 or 1. All these results 
indicate that most ILD progressors (>80%) could be identified 
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figure 1 Prediction success rate with SPAR score for progression of mild SSc interstitial lung disease. PPV, positive predictive value.
 o
n
 28 Novem
ber 2018 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214270 on 10 Novem
ber 2018. Downloaded from
 
2 Ann Rheum Dis Month 2018 Vol 0 No 0
correspondence response
when the patients fulfilled either of these two characteristics 
(SpO2 after 6MWT ≤94%, arthritis ever).
Meanwhile, patients with neither of these two characteristics 
had a really low chance (<10%) to have a deterioration of ILD 
in the next 1 year. This is further highlighted in figure 1. Thus, 
although further external validation and testing in clinical prac-
tice is still required, we believe that the SPAR model provides a 
promising risk-stratification tool in patients with mild SSc-ILD.
othEr PotEntial PrEdictorS
The authors may like to provide any data on other variables 
expected to predict progression—baseline extent of ILD on CT 
(varying from 0% to 20%), oesophageal diameter on HRCT and 
nailfold capillaroscopy.
Regarding the question on other potential predictors, we 
fully agree that other clinical variables could potentially predict 
ILD progression in patients with SSc. We collected data from 
nailfold capillaroscopy (NFC) in the derivation cohort. A total 
of 9/98 (9.2%) patients showed normal-like patterns, 20/98 
(20.4%) patients showed early scleroderma patterns, 33/98 
(33.7%) patients showed active scleroderma patterns and 36/98 
(36.7%) patients showed late scleroderma patterns, respec-
tively. The percentage of active/late scleroderma pattern did not 
differ significantly among ILD progressors and non-progres-
sors (72.0% vs 69.9%, p=0.840). After applying multivariate 
regression, active/late scleroderma pattern in NFC was also not 
predictive for ILD progression (p=0.138). Additionally, ‘SpO2 
after 6 MWT’ and ‘arthritis ever’ were still the only two signif-
icant predictors after NFC data were forced in the multivariate 
regression model.
Unfortunately, we did not have detailed data for exact extent 
of ILD or oesophageal diameter on HRCT in our cohort. We 
motivate to include these parameters in further studies.
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